Urinary Obstruction
9
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
NXT Post-Market Clinical Follow-up
Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent
Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis
The Effect of Urinating Through the Zipper or by Pulling Down the Trousers on Uroflowmetry Parameters in LUTS
Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial
Delta Q Value to Discriminate Detrusor Underactivity From Bladder Outlet Obstruction
The Importance of Non-invasive Methods in the Diagnosis of Lower Urinary System Symptoms.
BE Technologies Mobile Uroflowmetry Validation Study